ABBV•benzinga•
AbbVie Immunology Portfolio Poised For Growth Through Humira Erosion: Analyst
Summary
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2025 by benzinga